Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.83 |
| ▸ | LTA4H | P09960 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | NPY1R | P25929 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7808301 | 0.91 | HRH3 (0.69) | HRH3LTA4HHTTKMT2ANPC1 | |
| SCHEMBL4689454 | 0.88 | KDM4E (0.86) | HRH3LTA4HHTTNPC1RAB9A | |
| SCHEMBL7999188 | 0.87 | HRH3 (0.75) | HRH3LTA4HKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3581020 | 0.87 | NPC1 (0.87) | HRH3LTA4HHTTNPC1RAB9A | |
| SCHEMBL8107620 | 0.87 | HRH3 (0.75) | HRH3LTA4HKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL14970586 | 0.87 | NPC1 (0.87) | HRH3LTA4HHTTNPC1RAB9A | |
| SCHEMBL7402238 | 0.85 | KDM4E (0.85) | HRH3LTA4HHTTKMT2ANPC1 | |
| SCHEMBL20382580 | 0.84 | LTA4H (0.86) | HRH3LTA4HSIGMAR1 | |
| Hydrochloric Acid SCHEMBL7397479 | 0.84 | KDM4E (0.82) | HRH3LTA4HHTTKMT2ANPC1 | |
| SCHEMBL7402377 | 0.84 | KDM4E (0.85) | HRH3LTA4HHTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594563-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2594564-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594562-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594563-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594565-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2009117150-A2 | METHOD OF TREATING LUPUS WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008150486-A2 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |